The Avacta share price (AVCT) has climbed 1,400%. Here’s what I’d do now

The biotech sector has been one to watch since Covid-19 arrived. Could the Avacta Group share price be the one to beat in 2021 after its big 2020 surge?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Companies involved in Covid-19 testing have done well during the pandemic — and that includes Avacta Group (LSE: AVCT). The company released an update on its SARS-CoV-2 antigen lateral flow test on Monday, and the shares picked up 4% on the day. But that’s only a small part of the story — the Avacta share price has climbed a staggering 1,400% since the beginning of 2020.

We do need to see that in perspective, mind. Before Covid-19 turned up, there obviously wasn’t much call for Covid-19 testing. And Avacta was getting along with its cancer therapies and diagnostics. So a big boost to the Avacta share price since then is perhaps not surprising. But can it be sustained, and is there more growth to come?

First, let’s look at the latest news. The company mentions “recently announced data from a clinical study on 98 positive COVID-19 samples that demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads“. Avacta goes on to say it “expects to receive confirmation of the registration of the AffiDX in-vitro diagnostic device in the coming days, which will allow the group to immediately place the test on the market“.

Better than the competition

Chief executive Dr Alastair Smith added that, compared to two other commercially available lateral flow antigen tests, “the AffiDX test had better clinical sensitivity across the range of Ct values tested and, in particular, at lower viral loads“.

I take two immediate thoughts from that. The first is that the Avacta share price has gone on its sky-high, 1,000%+, ride even before the company had a saleable Covid-19 test. Wow! But secondly, if the Avacta test works better at lower viral loads, it could turn out to be very important indeed. Current lateral flow tests are not as accurate as laboratory tests that can take up to a couple of days to perform.

But where will the Avacta Group share price go for the rest of 2021 and beyond? Fellow Motley Fool writer Andy Ross recently suggested we could see another strong run in May. He could be right. I wouldn’t be surprised to see another leap upwards when the AffiDX test gets its expected approval. So would I buy the shares now?

Well, if ever there was a case where ‘past performance is no guide to future performance’ was apt, this is surely it. And I would not invest based solely on the short-term performance of anything. Saying that, there’s a good chance that Covid-19 will be with us long-term, just like influenza. And I can see demand for Covid-19 testing continuing for many more years.

Avacta share price valuation

But there’s another thing that puts me off high-flying growth shares like this. Avacta reported an operating loss in 2020, largely due to R&D spend. That makes it impossible for me to put any kind of rational valuation on the company. Is today’s price good value compared to future profits? Or is the Avacta share price pumped up much higher than it’s worth?

I have no idea, and I’ll keep away from the risk that comes with such uncertainty. But for any brave investors taking the chance, I wish them well.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in July [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

Warren Buffett’s Berkshire Hathaway dumped this growth stock. Here’s why I won’t

Eyebrows were raised when Warren Buffett's company invested in this Latin American fintech disruptor a few years ago. But now…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

£15k to spend? 3 UK shares, investment trusts and ETFs to consider for a £1,185 second income

By harnessing a range of different dividend stocks, I'm confident this mini portfolio might pay a large long-term second income.

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is Tesla stock about to crash?

Tesla stock was on the slide today, shedding around $80bn in market value. What's going on with the electric vehicle…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Should British investors consider buying Apple stock while it’s down 14% in 2025?

Apple stock has underperformed in 2025, falling more than 10%. Is this the buying opportunity UK investors have been waiting…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
US Stock

2 AI growth shares that I think are still undervalued

Jon Smith flags up two AI growth shares that aren't as overhyped as some peers, making them appealing for him…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Where is the next Nvidia stock right now?

Nvidia stock has delivered jaw-dropping gains. Here are 10 growth shares that have the potential to also produce big returns…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Could these FTSE 100 stocks explode in July?

Looking for FTSE stocks that could catch fire this month? Here are the share price prospects of two popular London…

Read more »